DFTX Definium Therapeutics, Inc.

Nasdaq Medicinal Chemicals & Botanical Products A1 CIK: 0001813814
AI RATING
HOLD
45% Confidence

Investment Thesis

Definium maintains a strong balance sheet with $262.5M in cash providing 6+ years of operational runway and demonstrates impressive 212% revenue growth. However, operating losses of -$59.2M combined with deteriorating EPS (-33.8% YoY) despite revenue growth indicate operational headwinds are accelerating, obscuring the path to profitability.

Strengths

  • + Strong cash position of $262.5M with sufficient runway to execute strategy
  • + Excellent liquidity metrics (4.69x current and quick ratios) provide financial flexibility
  • + Impressive 212% YoY revenue growth signals market traction from early stage
  • + Conservative capital structure with minimal debt (0.15x debt-to-equity ratio)

Risks

  • ! Massive operating losses (-$59.2M) and net losses (-$77.1M) with severely negative margins (-1270% operating margin)
  • ! Deteriorating EPS (-33.8% YoY) indicates losses accelerating faster than revenue growth, moving away from profitability
  • ! Minimal absolute revenue base ($4.7M) provides insufficient evidence of sustainable business model at scale

Key Metrics to Watch

Financial Metrics

Revenue
4.7M
Net Income
-77.1M
EPS (Diluted)
$-0.71
Free Cash Flow
-42.6M
Total Assets
401.3M
Cash
262.5M

Profitability Ratios

Gross Margin N/A
Operating Margin -1,269.7%
Net Margin -1,653.0%
ROE -27.6%
ROA -19.2%
FCF Margin -914.0%

Balance Sheet & Liquidity

Current Ratio
4.69x
Quick Ratio
4.69x
Debt/Equity
0.15x
Debt/Assets
30.5%
Interest Coverage
-47.57x
Long-term Debt
40.8M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: 2026-05-09T10:21:22.014680 | Data as of: 2026-03-31 | Powered by Claude AI